Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide

S. Patterson, M. de Kort, N. Irwin*, R.C. Moffett, W.H.A. Dokter, E.S. Bos, A.M.M. Miltenburg, P.R. Flatt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)



To examine the biological characteristics of a novel glucagon‐like peptide‐1 (GLP‐1) conjugate, in which an antithrombin III (ATIII)‐binding pentasaccharide is conjugated to d‐Ala8GLP‐1 using a tetraethylene glycol linker.


We assessed GLP‐1 receptor binding, cAMP generation and insulin secretory activity of the GLP‐1 conjugate in vitro. Circulating half‐life, glucose homeostatic and subchronic therapeutic effectiveness were then examined in vivo.


The half‐life of the GLP‐1 conjugate in mice was ∼11 h. In vitro insulin secretion from clonal β cells and islets was increased (p < 0.001) by the conjugate. The conjugate had half maximum effective concentration values of 1.3 × 10−7 and 9.9 × 10−8 M for displacement of 125I‐GLP‐1 in competitive GLP‐1 receptor binding and cAMP generation, respectively. Glucose tolerance in normal mice, immediately and 4 h after conjugate injection, resulted in significant (p < 0.001) improvements in blood glucose. These effects persisted for >48 h after administration. Daily treatment (21 days) of high‐fat‐fed and ob/ob mice with 25 nmol/kg conjugate resulted in significant improvement in glucose tolerance (p < 0.001) and reductions in glycated haemoglobin (HbA1c; p < 0.01) equivalent to or better than with exenatide or liraglutide. Treatment of C57BL/KsJ db/db mice for 15 days with 100 nmol/kg conjugate significantly (p < 0.001) reduced glucose and raised plasma insulin. Oral glucose tolerance was significantly (p < 0.001) improved and both 24‐h glucose profile (p < 0.001) and HbA1c levels (p < 0.001) were reduced. Islet size (p < 0.001) and pancreatic insulin content were increased without change of islet cell proliferation or apoptosis.


These data show that d‐Ala8GLP‐1(Lys37) pentasaccharide exerts significant antidiabetic actions and has a projected pharmacokinetic/pharmacodynamic profile that merits further evaluation in humans for a possible once‐weekly dosing regimen.

Original languageEnglish
Pages (from-to)760-770
Number of pages11
JournalDiabetes, Obesity and Metabolism
Issue number8
Early online date16 Jun 2015
Publication statusPublished - Aug 2015


  • glucagon-like peptide-1 (GLP-1)
  • glucose homeostasis
  • insulin secretion
  • pentasaccharide
  • liraglutide
  • GLP-1

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide'. Together they form a unique fingerprint.

Cite this